4570
Immuno-Biological Laboratories Co.,Ltd.
免疫生物研究所
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
602,749
Mar 2022
647,576
Mar 2023
794,621
Mar 2024
816,701
Mar 2025
969,533
Operating profit(thousand JPY)
Mar 2021
-240,984
Mar 2022
-122,219
Mar 2023
58,373
Mar 2024
104,299
Mar 2025
209,345
Operating profit margin(%)
Mar 2021
-39.98
Mar 2022
-18.87
Mar 2023
7.35
Mar 2024
12.77
Mar 2025
21.59
Profit before tax(thousand JPY)
Mar 2021
-310,630
Mar 2022
-250,142
Mar 2023
-280,611
Mar 2024
124,644
Mar 2025
209,861
Profit(thousand JPY)
Mar 2021
-318,827
Mar 2022
-258,767
Mar 2023
-289,731
Mar 2024
186,694
Mar 2025
249,047
Total assets(thousand JPY)
Mar 2021
1,838,038
Mar 2022
1,705,338
Mar 2023
1,434,337
Mar 2024
1,618,582
Mar 2025
1,845,390
Cash and cash equivalents(thousand JPY)
Mar 2021
552,022
Mar 2022
449,184
Mar 2023
561,997
Mar 2024
674,969
Mar 2025
770,563
Cash flows from operating activities(thousand JPY)
Mar 2021
-194,145
Mar 2022
-93,204
Mar 2023
26,458
Mar 2024
133,775
Mar 2025
183,495
Cash flows from investing activities(thousand JPY)
Mar 2021
-17,233
Mar 2022
-155,629
Mar 2023
30,036
Mar 2024
-24,496
Mar 2025
-53,660
Cash flows from financing activities(thousand JPY)
Mar 2021
-216,000
Mar 2022
143,998
Mar 2023
991
Mar 2024
991
Mar 2025
-31,755
Return on equity(%)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
15.9
Mar 2025
17.9
Equity ratio(%)
Mar 2021
88.5
Mar 2022
80.2
Mar 2023
75.2
Mar 2024
78.2
Mar 2025
82.1
Earnings per share(JPY per share)
Mar 2021
-34.23
Mar 2022
-27.78
Mar 2023
-31.1
Mar 2024
20.05
Mar 2025
26.74
Net assets per share(JPY per share)
Mar 2021
174.7
Mar 2022
146.92
Mar 2023
115.81
Mar 2024
135.85
Mar 2025
162.6
Dividend per share(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Payout ratio(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.